Compare · ABBV vs NVCT
ABBV vs NVCT
Side-by-side comparison of AbbVie Inc. (ABBV) and Nuvectis Pharma Inc. (NVCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and NVCT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $447.62B, about 620.6x NVCT ($721.2M).
- Over the past year, ABBV is up 34.8% and NVCT is up 251.9% - NVCT leads by 217.1 points.
- ABBV has been more active in the news (19 items in the past 4 weeks vs 7 for NVCT).
- ABBV has more recent analyst coverage (25 ratings vs 4 for NVCT).
- Company
- AbbVie Inc.
- Nuvectis Pharma Inc.
- Price
- $251.79+3.50%
- $27.18-2.53%
- Market cap
- $447.62B
- $721.2M
- 1M return
- +16.89%
- +167.31%
- 1Y return
- +34.82%
- +251.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2022
- News (4w)
- 19
- 7
- Recent ratings
- 25
- 4
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Nuvectis Pharma Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Latest ABBV
- SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
- AbbVie to Host Second-Quarter 2026 Earnings Conference Call
- The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
- SEC Form 11-K filed by AbbVie Inc.
- BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
- AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
Latest NVCT
- Nuvectis Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
- Director Hoberman Kenneth was granted 35,000 shares, increasing direct ownership by 26% to 168,140 units (SEC Form 4)
- Director Oliviero James F Iii was granted 35,000 shares, increasing direct ownership by 40% to 122,828 units (SEC Form 4)
- Director Sanchez Juan was granted 35,000 shares, increasing direct ownership by 45% to 113,380 units (SEC Form 4)
- Director Kaplan Matthew L. was granted 35,000 shares, increasing direct ownership by 28% to 159,760 units (SEC Form 4)
- Nuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- SEC Form 10-Q filed by Nuvectis Pharma Inc.
- Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits